drugset / Trial / NCT06737523
Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML
NaSingle-groupOpen-labelTreatment
Summary
To investigate the safety and efficacy of the CVA regimen, composed of Chiglitazar Sodium in combination with Venetoclax and Azacitidine, in the treatment of patients with refractory/relapsed acute myeloid leukemia (R/R AML).
Timeline
- Start
- 2025-03-15
- Primary completion
- 2025-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 100 mg | — |
| Subject | Chiglitazar | Unknown | 48 mg | — |
| Subject | Venetoclax | Small molecule | 400 mg | Oral |